Literature DB >> 6940150

Multiple functional domains of the heparin molecule.

G M Oosta, W T Gardner, D L Beeler, R D Rosenberg.   

Abstract

Affinity-fractionated porcine heparin was randomly scissioned by chemical techniques to give hexasaccharides, octasaccharides, decasaccharides, and mucopolysaccharide fragments of approximately 14 residues and approximately 16 residues that were able to complex with the protease inhibitor. Direct measurements of the kinetic behavior of the hexasaccharides, octasaccharides, and decasaccharides showed that these fractions greatly enhanced the rate of Factor Xa inactivation by antithrombin. Indeed, these species exhibited specific molar activities that ranged from 6.9% (hexaccharide) to 60.9% (decasaccharide) of that of the heparin fragment of approximately 16 residues. However, these oligosaccharides exhibited essentially no ability to accelerate thrombin-antithrombin interactions. The avidity of the hexasaccharides, octasaccharides, and decasaccharides for the protease inhibitor increased as a function of size with the respective dissociation constants ranging from 5.5 X 10(-6) M to 2.9 X 10(-7) M. These data suggest that the region of the heparin molecule needed for catalyzing Factor Xa-antithrombin interaction is intimately related to the antithrombin binding domain. The smallest complex carbohydrate fragment that accelerated the inactivation of thrombin by antithrombin had approximately 14 residues. This fraction had an avidity for the protease inhibitor of 2.8 X 10(-7) M and specific molar activities of 140 units per mumol (thrombin neutralization) and 460 units per mumol (factor Xa inactivation). The largest heparin fragment examined contained approximately 16 residues. This fraction had an avidity for antithrombin of 2.4 X 10(-7) M and specific molar activities of 500 units per mumol (thrombin neutralization) and 560 units per mumol (Factor Xa inactivation). Detailed kinetic analyses showed that these two species are able to directly activate antithrombin to the same extent with respect to thrombin inhibition. However, the larger mucopolysaccharide fragment is also capable of approximating free enzyme with protease inhibitor.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6940150      PMCID: PMC319896          DOI: 10.1073/pnas.78.2.829

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  10 in total

1.  A modified uronic acid carbazole reaction.

Authors:  T BITTER; H M MUIR
Journal:  Anal Biochem       Date:  1962-10       Impact factor: 3.365

2.  The separation of active and inactive forms of heparin.

Authors:  L H Lam; J E Silbert; R D Rosenberg
Journal:  Biochem Biophys Res Commun       Date:  1976-03-22       Impact factor: 3.575

3.  Anti-Xa active heparin oligosaccharides.

Authors:  J Choay; J C Lormeau; M Petitou; P Sinay; B Casu; P Oreste; G Torri; G Gatti
Journal:  Thromb Res       Date:  1980 May 1-15       Impact factor: 3.944

4.  The molecular size of the antithrombin-binding sequence in heparin.

Authors:  L Thunberg; G Bäckström; H Grundberg; J Riesenfeld; U Lindahl
Journal:  FEBS Lett       Date:  1980-08-11       Impact factor: 4.124

5.  On the molecular-weight-dependence of the anticoagulant activity of heparin.

Authors:  L Thunberg; U Lindahl; A Tengblad; T C Laurent; C M Jackson
Journal:  Biochem J       Date:  1979-07-01       Impact factor: 3.857

6.  Correlation between structure and function of heparin.

Authors:  R D Rosenberg; L Lam
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

7.  Structure of the antithrombin-binding site in heparin.

Authors:  U Lindahl; G Bäckström; M Höök; L Thunberg; L A Fransson; A Linker
Journal:  Proc Natl Acad Sci U S A       Date:  1979-07       Impact factor: 11.205

8.  Fractionation of low molecular weight heparin species and their interaction with antithrombin.

Authors:  D Beeler; R Rosenberg; R Jordan
Journal:  J Biol Chem       Date:  1979-04-25       Impact factor: 5.157

9.  Structure-function relationships of heparin species.

Authors:  R D Rosenberg; G Armand; L Lam
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

10.  The size and shape of human and bovine antithrombin III.

Authors:  B Nordenman; C Nyström; I Björk
Journal:  Eur J Biochem       Date:  1977-08-15
  10 in total
  36 in total

1.  Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity.

Authors:  L C Chang; J F Liang; H F Lee; L M Lee; V C Yang
Journal:  AAPS PharmSci       Date:  2001

2.  Cell mutants defective in synthesizing a heparan sulfate proteoglycan with regions of defined monosaccharide sequence.

Authors:  A L De Agostini; H K Lau; C Leone; H Youssoufian; R D Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

3.  Chemoenzymatic synthesis of heparin oligosaccharides with both anti-factor Xa and anti-factor IIa activities.

Authors:  Yongmei Xu; Elizabeth H Pempe; Jian Liu
Journal:  J Biol Chem       Date:  2012-07-06       Impact factor: 5.157

Review 4.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

5.  Interaction of heparin with fibronectin and isolated fibronectin domains.

Authors:  K C Ingham; S A Brew; D H Atha
Journal:  Biochem J       Date:  1990-12-15       Impact factor: 3.857

6.  Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis.

Authors:  U Schmitz-Huebner; H Bünte; G Freise; B Reers; C Rüschemeyer; R Scherer; H Schulte; J van de Loo
Journal:  Klin Wochenschr       Date:  1984-04-16

7.  Heparin-catalyzed inhibitor/protease reactions: kinetic evidence for a common mechanism of action of heparin.

Authors:  M J Griffith
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

Review 8.  Anticoagulation therapy in children.

Authors:  Milind D Ronghe; Christina Halsey; Nicholas J Goulden
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  Structure-function relations of heparin-mimetic sulfated xylan oligosaccharides: inhibition of human immunodeficiency virus-1 infectivity in vitro.

Authors:  A L Stone; D J Melton; M S Lewis
Journal:  Glycoconj J       Date:  1998-07       Impact factor: 2.916

10.  Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4.

Authors:  D A Lane; J Denton; A M Flynn; L Thunberg; U Lindahl
Journal:  Biochem J       Date:  1984-03-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.